Tags

Type your tag names separated by a space and hit enter

Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
Urology. 2013 Sep; 82(3):660-5.U

Abstract

OBJECTIVE

To assess the influence of carvedilol, an α- and β-blocker, on lower urinary tract symptoms (LUTS) and urine flow in hypertensive patients with benign prostatic hyperplasia (BPH).

METHODS

Fifty men were included in this double blind crossover study with placebo. After initial screening, participants were randomized to the carvedilol or the enalapril group, with cross over after 3 months. Doses of both drugs were uptitrated or additional therapy was introduced to ensure normal control of blood pressure (BP). Urologic assessment included uroflowmetry (average [Qavg] and maximum urinary flow rate [Qmax]), postvoid residual urine volume (PVR), International Prostate Symptom Score (IPSS), and prostate-specific antigen (PSA).

RESULTS

After carvedilol or enalapril administration, BP values were significantly reduced, whereas heart rate decreased only in the carvedilol group. Basal urologic values for carvedilol and enalapril were similar: Qavg, 7.8 ± 0.9 and 8.1 ± 0.6 mL/s; Qmax, 13.2 ± 1.5 and 13.7 ± 0.9 mL/s; PVR, 86.1 ± 13.2 and 85.6 ± 11.7 mL; and IPSS, 13.2 ± 0.9 and 12.3 ± 0.8 points, respectively. After treatment with carvedilol, PVR and IPSS significantly decreased (48.2 ± 11.7 mL, 9.0 ± 0.8 points, respectively; P <.001), whereas Qavg and Qmax increased (10.3 ± 0.9 mL/s, 16.5 ± 1.4 mL/s, respectively; P <.001). In the enalapril group, all of these values remained unchanged.

CONCLUSION

Carvedilol, compared with enalapril, has a positive influence on LUTS related to BPH in patients with hypertension. Thus, therapy with carvedilol may be considered in hypertensive patients with BPH. Further studies on the urologic benefit from long-term use of the drug are warranted.

Authors+Show Affiliations

Department of Internal Diseases, Hypertension and Angiology, Medical University of Warsaw, Warsaw, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23987161

Citation

Lewandowski, Jacek, et al. "Beneficial Influence of Carvedilol On Urologic Indices in Patients With Hypertension and Benign Prostatic Hyperplasia: Results of a Randomized, Crossover Study." Urology, vol. 82, no. 3, 2013, pp. 660-5.
Lewandowski J, Sinski M, Symonides B, et al. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. Urology. 2013;82(3):660-5.
Lewandowski, J., Sinski, M., Symonides, B., Korecki, J., Rogowski, K., Judycki, J., Sieczych, A., Możeńska, O., & Gaciong, Z. (2013). Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. Urology, 82(3), 660-5. https://doi.org/10.1016/j.urology.2013.03.087
Lewandowski J, et al. Beneficial Influence of Carvedilol On Urologic Indices in Patients With Hypertension and Benign Prostatic Hyperplasia: Results of a Randomized, Crossover Study. Urology. 2013;82(3):660-5. PubMed PMID: 23987161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. AU - Lewandowski,Jacek, AU - Sinski,Maciej, AU - Symonides,Bartosz, AU - Korecki,Jerzy, AU - Rogowski,Krzysztof, AU - Judycki,Jacek, AU - Sieczych,Artur, AU - Możeńska,Olga, AU - Gaciong,Zbigniew, PY - 2012/12/27/received PY - 2013/03/22/revised PY - 2013/03/30/accepted PY - 2013/8/31/entrez PY - 2013/8/31/pubmed PY - 2013/12/18/medline SP - 660 EP - 5 JF - Urology JO - Urology VL - 82 IS - 3 N2 - OBJECTIVE: To assess the influence of carvedilol, an α- and β-blocker, on lower urinary tract symptoms (LUTS) and urine flow in hypertensive patients with benign prostatic hyperplasia (BPH). METHODS: Fifty men were included in this double blind crossover study with placebo. After initial screening, participants were randomized to the carvedilol or the enalapril group, with cross over after 3 months. Doses of both drugs were uptitrated or additional therapy was introduced to ensure normal control of blood pressure (BP). Urologic assessment included uroflowmetry (average [Qavg] and maximum urinary flow rate [Qmax]), postvoid residual urine volume (PVR), International Prostate Symptom Score (IPSS), and prostate-specific antigen (PSA). RESULTS: After carvedilol or enalapril administration, BP values were significantly reduced, whereas heart rate decreased only in the carvedilol group. Basal urologic values for carvedilol and enalapril were similar: Qavg, 7.8 ± 0.9 and 8.1 ± 0.6 mL/s; Qmax, 13.2 ± 1.5 and 13.7 ± 0.9 mL/s; PVR, 86.1 ± 13.2 and 85.6 ± 11.7 mL; and IPSS, 13.2 ± 0.9 and 12.3 ± 0.8 points, respectively. After treatment with carvedilol, PVR and IPSS significantly decreased (48.2 ± 11.7 mL, 9.0 ± 0.8 points, respectively; P <.001), whereas Qavg and Qmax increased (10.3 ± 0.9 mL/s, 16.5 ± 1.4 mL/s, respectively; P <.001). In the enalapril group, all of these values remained unchanged. CONCLUSION: Carvedilol, compared with enalapril, has a positive influence on LUTS related to BPH in patients with hypertension. Thus, therapy with carvedilol may be considered in hypertensive patients with BPH. Further studies on the urologic benefit from long-term use of the drug are warranted. SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/23987161/Beneficial_influence_of_carvedilol_on_urologic_indices_in_patients_with_hypertension_and_benign_prostatic_hyperplasia:_results_of_a_randomized_crossover_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(13)00690-0 DB - PRIME DP - Unbound Medicine ER -